Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunovia ABIMMVF -61.59%41 3-Year EBITDA Growth Rate is 43.20% as of Jun. 2026. GuruFocus rates IMMVF with a GF Score™ of 41/100 and a GF Value™ of $0.02. The stock has 6 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, Immunovia AB ranks better than 80.61% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 43.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 27.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -10.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Immunovia AB was 43.20% per year. The lowest was -115.20% per year. And the median was -24.10% per year.
Immunovia AB (OTCPK:IMMVF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Immunovia AB 3-Year EBITDA Growth Rate Related Terms
IMMVF vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Immunovia AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Immunovia AB's 3-Year EBITDA Growth Rate falls into.
Immunovia AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 43.20% mean?
Immunovia AB (IMMVF) has a 3-Year EBITDA Growth Rate of 43.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Immunovia AB and its competitors. According to the industry distribution chart, Immunovia AB ranks #32 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 19.4%.
Is Immunovia AB's 3-Year EBITDA Growth Rate too high?
Immunovia AB's current 3-Year EBITDA Growth Rate is 43.20%. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. Immunovia AB's value of 43.20% is 292.7% above this industry median. Based on the distribution chart, Immunovia AB ranks #32 out of 165 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #32 out of 165 companies for 3-Year EBITDA Growth Rate. This places Immunovia AB in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. Immunovia AB's value of 43.20% is 292.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current 3-Year EBITDA Growth Rate of 43.20% is 292.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current 3-Year EBITDA Growth Rate is 43.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current 3-Year EBITDA Growth Rate of 43.20%. The stock's GF Value™ is $0.02, compared to a current price of $0.02 — trading right at its estimated fair value. The current 3-Year EBITDA Growth Rate is 43.20% and 292.7% above the Medical Diagnostics & Research industry median of 11.00. Immunovia AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current 3-Year EBITDA Growth Rate is 43.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be undervalued.
The current stock price of $0.02 is trading 0% below its estimated GF Value™ of $0.02.
Key valuation signals for IMMVF:
3-Year EBITDA Growth Rate: 43.20%
GF Value™: $0.02 vs. price of $0.02 (0% below fair value)
Industry Position: 292.7% above the Medical Diagnostics & Research median (#32 of 165)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
41GF Score
Get the complete analysis for IMMVF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
